Please use this identifier to cite or link to this item:
https://ir.swu.ac.th/jspui/handle/123456789/12289
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Leechaisit R. | |
dc.contributor.author | Pingaew R. | |
dc.contributor.author | Prachayasittikul V. | |
dc.contributor.author | Worachartcheewan A. | |
dc.contributor.author | Prachayasittikul S. | |
dc.contributor.author | Ruchirawat S. | |
dc.contributor.author | Prachayasittikul V. | |
dc.date.accessioned | 2021-04-05T03:02:35Z | - |
dc.date.available | 2021-04-05T03:02:35Z | - |
dc.date.issued | 2019 | |
dc.identifier.issn | 9680896 | |
dc.identifier.other | 2-s2.0-85070395327 | |
dc.identifier.uri | https://ir.swu.ac.th/jspui/handle/123456789/12289 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85070395327&doi=10.1016%2fj.bmc.2019.08.001&partnerID=40&md5=6bf733408e7c36b895365a553545d17e | |
dc.description.abstract | A library of bis-sulfonamides (9–26) were synthesized and tested for their aromatase inhibitory activities. Interestingly, all bis-sulfonamide derivatives inhibited the aromatase with IC50 range of 0.05–11.6 μM except for compound 23. The analogs 15 and 16 bearing hydrophobic chloro and bromo groups exhibited the potent aromatase inhibitory activity in sub-micromolar IC50 values (i.e., 50 and 60 nM, respectively) with high safety index. Molecular docking revealed that the chloro and bromo benzenesulfonamides (15 and 16) may play role in the hydrophobic interaction with Leu477 of the aromatase to mimic steroidal backbone of the natural substrate, androstenedione. QSAR study also revealed that the most potent activity of compounds was governed by van der Waals volume (GATS6v) and mass (Mor03m) descriptors. Finally, the two compounds (15 and 16) were highlighted as promising compounds to be further developed as novel aromatase inhibitors. © 2019 Elsevier Ltd | |
dc.subject | androstenedione | |
dc.subject | aromatase | |
dc.subject | benzenesulfonamide derivative | |
dc.subject | doxorubicin | |
dc.subject | letrozole | |
dc.subject | n,n' (1,3 phenylene)bis(4 chlorobenzenesulfonamide) | |
dc.subject | n,n' (1,3 phenylene)bis(4 methoxybenzenesulfonamide) | |
dc.subject | n,n' [1,3 phenylenebis(methylene)]bis(2 nitrobenzenesulfonamide) | |
dc.subject | n,n' [1,3 phenylenebis(methylene)]bis(2,3,5,6 tetramethylbenzenesulfonamide) | |
dc.subject | n,n' [1,3 phenylenebis(methylene)]bis(3 aminobenzenesulfonamide) | |
dc.subject | n,n' [1,3 phenylenebis(methylene)]bis(3 nitrobenzenesulfonamide) | |
dc.subject | n,n' [1,3 phenylenebis(methylene)]bis(4 acetylbenzenesulfonamide) | |
dc.subject | n,n' [1,3 phenylenebis(methylene)]bis(4 bromobenzenesulfonamide) | |
dc.subject | n,n' [1,3 phenylenebis(methylene)]bis(4 chlorobenzenesulfonamide) | |
dc.subject | n,n' [1,3 phenylenebis(methylene)]bis(4 cyanobenzenesulfonamide) | |
dc.subject | n,n' [1,3 phenylenebis(methylene)]bis(4 fluorobenzenesulfonamide) | |
dc.subject | n,n' [1,3 phenylenebis(methylene)]bis(4 methoxybenzenesulfonamide) | |
dc.subject | n,n' [1,3 phenylenebis(methylene)]bis(4 methylbenzenesulfonamide) | |
dc.subject | n,n' [1,3 phenylenebis(methylene)]bis(4 nitrobenzenesulfonamide) | |
dc.subject | n,n' [1,3 phenylenebis(methylene)]bis(4 trifluoromethylbenzenesulfonamide) | |
dc.subject | n,n' [1,3 phenylenebis(methylene)]bis(naphthalene 2 sulfonamide) | |
dc.subject | n,n' [1,4 phenylenebis(methylene)]bis(2,3,5,6 tetramethylbenzenesulfonamide) | |
dc.subject | n,n' [1,4 phenylenebis(methylene)]bis(4 cyanobenzenesulfonamide) | |
dc.subject | sulfonamide | |
dc.subject | unclassified drug | |
dc.subject | aromatase | |
dc.subject | aromatase inhibitor | |
dc.subject | protein binding | |
dc.subject | sulfonamide | |
dc.subject | Article | |
dc.subject | breast cancer | |
dc.subject | controlled study | |
dc.subject | drug cytotoxicity | |
dc.subject | drug potency | |
dc.subject | drug safety | |
dc.subject | drug structure | |
dc.subject | drug synthesis | |
dc.subject | enzyme inhibition | |
dc.subject | hydrophobicity | |
dc.subject | IC50 | |
dc.subject | molecular docking | |
dc.subject | MRC-5 cell line | |
dc.subject | quantitative structure activity relation | |
dc.subject | structure activity relation | |
dc.subject | T-47D cell line | |
dc.subject | binding site | |
dc.subject | chemical structure | |
dc.subject | chemistry | |
dc.subject | human | |
dc.subject | metabolism | |
dc.subject | molecular library | |
dc.subject | pharmacology | |
dc.subject | synthesis | |
dc.subject | tumor cell line | |
dc.subject | Aromatase | |
dc.subject | Aromatase Inhibitors | |
dc.subject | Binding Sites | |
dc.subject | Cell Line, Tumor | |
dc.subject | Humans | |
dc.subject | Molecular Docking Simulation | |
dc.subject | Molecular Structure | |
dc.subject | Protein Binding | |
dc.subject | Quantitative Structure-Activity Relationship | |
dc.subject | Small Molecule Libraries | |
dc.subject | Sulfonamides | |
dc.title | Synthesis, molecular docking, and QSAR study of bis-sulfonamide derivatives as potential aromatase inhibitors | |
dc.type | Article | |
dc.rights.holder | Scopus | |
dc.identifier.bibliograpycitation | Bioorganic and Medicinal Chemistry. Vol 27, No.19 (2019) | |
dc.identifier.doi | 10.1016/j.bmc.2019.08.001 | |
Appears in Collections: | Scopus 1983-2021 |
Files in This Item:
There are no files associated with this item.
Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.